Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.

被引：0

作者：

Mohty, Mohamad

Tomasson, Michael H.

Arnulf, Bertrand

Bahlis, Nizar J.

Prince, H. Miles

Niesvizky, Ruben

Rodriguez-Otero, Paula

Martinez-Lopez, Joaquin

Koehne, Guenther

Jethava, Yogesh

Gabayan, A. Eli

Stevens, Don A.

Nooka, Ajay K.

Raje, Noopur S.

Iida, Shinsuke

Leip, Eric

Conte, Umberto

Czibere, Akos Gabor

Viqueira, Andrea

Lesokhin, Alexander M.

机构：

[1] Sorbonne Univ, Hop St Antoine, Paris, France

[2] INSERM UMRs938, Paris, France

[3] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA

[4] Hop St Louis, Paris, France

[5] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[6] Epworth Healthcare, Melbourne, Vic, Australia

[7] Weill Cornell Med Coll, New York Presbyterian Hosp, New York, NY USA

[8] Univ Navarra Clin, Madrid, Spain

[9] Hosp Univ 12 OCTUBRE, Madrid, Spain

[10] Miami Canc Inst, Miami, FL USA

[11] Indiana Blood & Marrow Transplant, Indianapolis, IN USA

[12] Beverly Hills Canc Ctr, Beverly Hills, CA USA

[13] Norton Canc Inst, Louisville, KY USA

[14] Emory Univ Hosp, Winship Canc Inst, Atlanta, GA USA

[15] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[16] Nagoya City Univ, Dept Hematol & Oncol, Grad Sch Med Sci, Nagoya, Aichi, Japan

[17] Pfizer Inc, Cambridge, MA USA

[18] Pfizer Inc, New York, NY USA

[19] Pfizer SLU, Madrid, Spain

[20] Mem Sloan Kettering Canc Ctr, Div Hematol & Oncol, Weill Cornell Med Coll, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8039

引用

页数：1

共 50 条

[1] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
Raab, M. S.
Haenel, M.
Mohty, M.
Tomasson, M. H.
Arnulf, B.
Bahlis, N. J.
Prince, H. M.
Niesvizky, R.
Rodriguez-Otero, P.
Martinez-Lopez, J.
Koehne, G.
Jethava, Y.
Gabayan, A. E.
Stevens, D. A.
Nooka, A. K.
Raje, N.
Iida, S.
Leip, E.
Conte, U.
Czibere, A.
Viqueira, A.
Lesokhin, A. M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 177 - 178
[2] Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/ Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study
Mohty, Mohamad
Tomasson, Michael H.
Arnulf, Bertrand
Bahlis, Nizar J.
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Jethava, Yogesh
Gabayan, Afshin E.
Stevens, Don A.
Nooka, Ajay K.
Raje, Noopur
Iida, Shinsuke
Leip, Eric
Conte, Umberto
Czibere, Akos
Viqueira, Andrea
Lesokhin, Alexander M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S493 - S494
[3] Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
Lesokhin, Alexander M.
Arnulf, Bertrand
Niesvizky, Ruben
Mohty, Mohamad
Bahlis, Nizar J.
Tomasson, Michael H.
Rodriguez-Otero, Paula
Quach, Hang
Raje, Noopur S.
Iida, Shinsuke
Raab, Marc-Steffen
Czibere, Akos
Sullivan, Sharon
Leip, Eric
Viqueira, Andrea
Leleu, Xavier
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
Bahlis, Nizar J.
Raje, Noopur S.
Costello, Caitlin
Dholaria, Bhagirathbhai R.
Solh, Melhem M.
Levy, Moshe Y.
Tomasson, Michael H.
Dube, Harman
Liu, Feng
Liao, Kai Hsin
Basu, Cynthia
Skoura, Athanasia
Chan, Edward Michael
Trudel, Suzanne
Jakubowiak, Andrzej J.
Chu, Michael P.
Gasparetto, Cristina
Dalovisio, Andrew
Sebag, Michael
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naive to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
Bahlis, Nizar Jacques
Tomasson, Michael H.
Mohty, Mohamad
Niesvizky, Ruben
Nooka, Ajay K.
Manier, Salomon
Maisel, Christopher
Jethava, Yogesh
Martinez-Lopez, Joaquin
Prince, H. Miles
Arnulf, Bertrand
Rodriguez Otero, Paula
Koehne, Guenther
Touzeau, Cyrille
Raje, Noopur
Iida, Shinsuke
Raab, Marc-Steffen
Leip, Eric
Sullivan, Sharon
Conte, Umberto
Viqueira, Andrea
Lesokhin, Alexander M.
BLOOD, 2022, 140
[6] Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Garfall, Alfred L.
Usmani, Saad Z.
Mateos, Maria-Victoria
Nahi, Hareth
van de Donk, Niels W. C. J.
San-Miguel, Jesus F.
Rocafiguera, Albert Oriol
Rosinol, Laura
Chari, Ajai
Bhutani, Manisha
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Stephenson, Tara
Goldberg, Jenna D.
Banerjee, Arnob
Krishnan, Amrita
BLOOD, 2020, 136
[7] MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)
Levy, Moshe
Bahlis, Nizar
Raje, Noopur
Costello, Caitlin
Dholaria, Bhagirathbhai
Solh, Melhem
Tomasson, Michael
Dube, Harman
Damore, Michael
Lon, Hoi Kei
Basu, Cynthia
Skoura, Athanasia
Chan, Edward
Trudel, Suzanne
Jakubowiak, Andrzej
Chu, Michael
Gasparetto, Cristina
Dalovisio, Andrew
Sebag, Michael
Lesokhin, Alexander
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S439 - S439
[8] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
Cortes-Selva, Diana
Casneuf, Tineke
Vishwamitra, Deeksha
Stein, Sarah
Perova, Tatiana
Skerget, Sheri
Ramos, Elena
van Steenbergen, Laure
De Maeyer, Dries
Boominathan, Rengasamy
Lau, Onsay
Davis, Cuc
Banerjee, Arnob
Stephenson, Tara
Uhlar, Clarissa M.
Kobos, Rachel
Goldberg, Jenna D.
Pei, Lixia
Trancucci, Danielle
Girgis, Suzette
Lin, Shun Xin Wang
Wu, Liviawati S.
Moreau, Philippe
Usmani, Saad
Bahlis, Nizar Jacques
Van de Donk, Niels W. C. J.
Verona, Raluca
BLOOD, 2022, 140
[9] Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca I.
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S25 - S26
[10] Long-term follow-up from MajesTEC-1 of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Donk, Van De N. W.
Moreau, P.
Garfall, A. L.
Bhutani, M.
Oriol, A.
Nooka, A. K.
Martin, T. G.
Rosinol, L.
Mateos, M. -V.
Bahlis, N.
Popat, R.
Besemer, B.
Lopez, Martinez J.
Krishnan, A.
Delforge, M.
Trancucci, D.
Verona, R., I
Stephenson, T.
Chastain, K.
Sidana, S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 124 - 124

← 1 2 3 4 5 →